NewsUp one level
The Opening Session of the European Summit for Clinical Nanomedicine 2014 is now available on YouTube.
Registration for the IMI 2 Info Day on 30 September in Brussels, Belgium is now open via the event web page.
Dr Laurent Lévy speaks to Hannah Stanwix, Commissioning Editor. L Lévy is the Co-Founder, CEO, President of the Executive Board and a shareholder of Nanobiotix, a clinical-stage nanomedicine company pioneering NanoXray, a novel approach for the local treatment of cancer. L Lévy is the Vice-Chairman of the European Technology Platform on Nanomedicine (ETPN)
euMatch is the new matchmaking tool supporting partnering and partner search for your efficient participation in EU Horizon 2020 programme
As the SME Instrument is a brand new funding opportunity, it was not known what to expect from the first round of applications. As it is said on many occasions, the Instrument is very selective and only the best of the best can succeed.
Nanomedicine is an emerging space with many companies spending on research to explore this field in greater depth. Nanoparticles, which are of one to 100 nm, because of their characteristic of being very small are perfect for reaching cellular levels. Research in this field can open new avenues of treating diseases which were initially considered untreatable.
The parts of the Work Programmes 2014–2015 that relate to 2015 (topics, dates, budget) have, with these revised versions, been updated.
The ETP Nanomedicine is currently expanding its range of collaborations with non-European countries in order to create new opportunities for its members. Besides USA, first contacts have been established with Argentina.
The Fit4Health project organises a webinar on 9th September focussed on the description and implementation of clinical trials in Horizon 2020 proposals.
DG SANCO launched a Public Consultation on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices
The European Commission and the Scientific Committee on Emerging Newly Identified Health Risks have launched a public consultation on the Preliminary opinion ‘Guidance on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices’.
The projects launched in the 1st Joint Translational Call in 2009 for research groups operating in the EuroNanoMed II partner countries have been finished.
The Innovative Medicines Initiative2 launched on open consultation for Idea generation and development of Call topics
The EU-Japan Centre is organizing a nanotech mission to Japan targeting EU Cluster and SMEs operating in that sector.
Nanobiomedicine is an international, peer-reviewed, open access scientific journal with an innovative approach, being open to both the readers and the authors (no fee requested).
CTO (Chief Technology Officer) of the Year award is a new platform to promote the importance of technology and innovation in Europe. The award will be given to the most innovative technology leader of a highly successful European company: a person who is both an inspiring leader and a foresighted technology manager. The award will recognize the most successful technology leaders in two categories: SMEs and large corporations.
Press Release: New European research project aims to tackle antibiotic resistance issue raised by WHO via inhalable nanotherapeutics
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
EuroNanomed 2 releases a 7-minute video to promote drug delivery using Nanoparticles
Five Public-private partnerships between the EC and industry have today published their first call for proposals, among them IMI2 and ECSEL
A new Guide on Synergies between European Structural and Investment Funds (ESIF), Horizon 2020 and other innovation and competitiveness related EU programmes is now available.
Road Map updated - Action Plan Against the rising threats from Antimicrobial Resistance
Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, announced today the acquisition of the ACT portfolio and related assets from Actium Biosystems, LLC. This move extends Endomagnetics’ oncology platform from diagnostics into therapeutics while maintaining synergies with its magnetic nanoparticle technology.
The ETPN released its Newsletter 2/2014, compiling internal news but also nanomedicine news, upcoming events, information on future calls, ...
The ETPN Annual Event and General Assembly 2014 will take place on 15th and 16th October 2014 in San Sebastian (Spain). The registration facility is now open!
Nanonica Prize 2014 awards scientists whose research achievements during last year represented a breakthrough in nanotechnology’s community.
BIND Therapeutics Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.